Invivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 18,425 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 18,425 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $15,477.00. Following the transaction, the insider directly owned 178,937 shares of the company’s stock, valued at approximately $150,307.08. This represents a 9.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Monday, August 17th, Timothy Edward Lee sold 22,355 shares of Invivyd stock. The shares were sold at an average price of $0.72, for a total value of $16,095.60.

Invivyd Trading Up 17.2%

Shares of IVVD opened at $0.87 on Wednesday. The firm has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The stock has a 50 day moving average of $0.77 and a 200-day moving average of $1.23. Invivyd, Inc. has a 52 week low of $0.48 and a 52 week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The business had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. On average, sell-side analysts predict that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Analyst Upgrades and Downgrades

IVVD has been the subject of several recent analyst reports. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Invivyd has an average rating of “Hold” and an average price target of $8.00.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently modified their holdings of IVVD. United Capital Financial Advisors LLC acquired a new position in Invivyd during the 2nd quarter worth $84,000. Bank of America Corp DE bought a new stake in shares of Invivyd in the 2nd quarter worth approximately $311,000. Jupiter Topco LLC bought a new position in Invivyd in the second quarter worth $30,048,000. ADAR1 Capital Management LLC bought a new position in shares of Invivyd during the 2nd quarter worth about $3,322,000. Finally, The Manufacturers Life Insurance Company bought a new position in Invivyd during the second quarter worth about $52,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.